Potential EU approval for Biogen's Alzheimer's drug underway; shares rise
View all comments(0)
Shares of drugmaker Biogen BIIB.O rise 2.8% to $118.42
BIIB says that the final process for the European Commission's decision on the marketing authorization application for the company's Alzheimer's drug lecanemab is underway
The update comes after the reconfirmation of the positive opinion for the drug's approval by the Committee for Medicinal Products for Human Use (CHMP) in February 2025
The therapy, already approved in U.S. and many other countries, could become Europe's first drug approved to treat the neurodegenerative condition directly rather than just its symptoms
As of last close, stock has fallen 23.1% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Hantavirus Appears Sporadically, Is Now the Opportunity to Buy Vaccine Concept Stock Moderna?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.